What do systematic reviews say?

Berotralstat vs placebo or active control

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 130 participants
  Moderate

Berotralstat vs placebo or active control

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 50 participants
  Low

C1 esterase inhibitor vs placebo or active control

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 36 participants
  Low

Plasma‐derived C1 esterase inhibitor vs placebo or active control

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 31 participants
  Low

Nanofiltered C1 esterase inhibitor vs placebo or active control

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 16 participants
  Very low

Nanofiltered C1 esterase inhibitor vs placebo or active control

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 16 participants
  Very low

Lanadelumab vs placebo or active control

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 68 participants
  Low

Lanadelumab vs placebo or active control

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 64 participants
  Low

Avoralstat vs placebo

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 93 participants
  Moderate

Cemented vs uncemented hemiarthroplasty

• Arthroplasties for hip fracture in adults 2022 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 1275 participants
  Moderate

Total hip arthroplasty vs hemiarthroplasty

• Arthroplasties for hip fracture in adults 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 83 participants
  Low

Any intervention vs steroid alone or plus levofloxacin

It is very uncertain whether any intervention changes proportion of eyes in which SEI had developed within 21 days of… compared with steroid alone or plus levofloxacin (very low certainty).

• Topical pharmacologic interventions versus placebo for epidemic keratoconjunctivitis 2022 · Cochrane Headline outcomes only
  RR 0.08 [0.01, 0.55]
  2 studies · 69 participants
  Very low

Any intervention vs steroid alone or plus levofloxacin

The review found no eligible studies for this question.

• Topical pharmacologic interventions versus placebo for epidemic keratoconjunctivitis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Topical steroid vs artificial tears

It is very uncertain whether topical steroid changes proportion of participants in whose eyes SEI had developed within 21… compared with artificial tears (very low certainty).

• Topical pharmacologic interventions versus placebo for epidemic keratoconjunctivitis 2022 · Cochrane Headline outcomes only
  RR 2.2 [0.89, 5.41]
  1 study · 50 participants
  Very low

Topical steroid vs artificial tears

The review found no eligible studies for this question.

• Topical pharmacologic interventions versus placebo for epidemic keratoconjunctivitis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Any intervention vs artificial tears or saline

It is very uncertain whether any intervention changes proportion of participants in whose eyes SEIs had developed within… compared with artificial tears or saline (very low certainty).

• Topical pharmacologic interventions versus placebo for epidemic keratoconjunctivitis 2022 · Cochrane Headline outcomes only
  RR 0.24 [0.1, 0.56]
  2 studies · 77 participants
  Very low

Any intervention vs artificial tears or saline

The review found no eligible studies for this question.

• Topical pharmacologic interventions versus placebo for epidemic keratoconjunctivitis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Methotrexate vs mycophenolate

It is very uncertain whether methotrexate changes proportion of participants with confirmed macular edema (lower… compared with mycophenolate (very low certainty).

• Non‐biologic, steroid‐sparing therapies for non‐infectious intermediate, posterior, and panuveitis in adults 2022 · Cochrane Headline outcomes only
  RR 0.49 [0.19, 1.3]
  1 study · 35 participants
  Very low

Methotrexate vs mycophenolate

Methotrexate showed no clear difference in proportion of participants experiencing complications or requiring… compared with mycophenolate (low certainty).

• Non‐biologic, steroid‐sparing therapies for non‐infectious intermediate, posterior, and panuveitis in adults 2022 · Cochrane Headline outcomes only
  RR 0.99 [0.43, 2.27]
  2 studies · 296 participants
  Low

Steroids with or without azathioprine vs cyclosporine A

• Non‐biologic, steroid‐sparing therapies for non‐infectious intermediate, posterior, and panuveitis in adults 2022 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 91 participants
  Very low